Skip to main content
Top
Published in: Calcified Tissue International 3/2007

01-03-2007 | Clinical Investigations

Burden of Hip Fracture in Iran

Authors: S. Ahmadi-Abhari, A. Moayyeri, F. Abolhassani

Published in: Calcified Tissue International | Issue 3/2007

Login to get access

Abstract

To measure the burden caused by hip fracture in Iran and to compare it with other parts of the world, we applied the Global Burden of Disease (GBD) method created by the World Health Organization. The GBD method uses disability-adjusted life years (DALY), which is comprised of years of life lost (YLL) and years of life lived with disability (YLD). To calculate YLD, incidence of hip fracture was obtained from the Iranian Multicenter Study on Accidental Injuries, a large-scale nationwide prospective study. Disability weights were applied to the remaining duration of disease. To calculate YLL, remaining years of potential life at any age at death were calculated using the standard life table. A discount rate of 3% and age weighting were applied. Hip fracture generated 16,708 DALYs, comprising 8,812 (52.7%) YLL and 7,896 (47.3%) YLD. Iran accounted for 0.85% of the global burden of hip fracture and 12.4% of the burden of hip fracture in the Middle East. The female to male ratio in Iran (1.1) was lower than the global (2.2) and the Middle Eastern (1.4) ratios and higher than the ratios in China and India (1.0 and 0.9, respectively). In conclusion, hip fracture is not as much a cause of disease burden in Iran as in the developed regions of the world. We recommend utilization of the standardized GBD method to calculate burden of osteoporosis in different countries and to set local priorities according to these measures.
Appendix
Available only for authorised users
Literature
1.
go back to reference Melton LJ 3rd (1996) Epidemiology of hip fractures: implications of the exponential increase with age. Bone 18:121S–125SPubMedCrossRef Melton LJ 3rd (1996) Epidemiology of hip fractures: implications of the exponential increase with age. Bone 18:121S–125SPubMedCrossRef
2.
go back to reference Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427PubMedCrossRef Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427PubMedCrossRef
3.
go back to reference Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289PubMedCrossRef Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289PubMedCrossRef
4.
go back to reference Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413PubMedCrossRef Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413PubMedCrossRef
5.
go back to reference Melton LJ 3rd (1993) Hip fractures: a worldwide problem today and tomorrow. Bone 1:S1–S8CrossRef Melton LJ 3rd (1993) Hip fractures: a worldwide problem today and tomorrow. Bone 1:S1–S8CrossRef
6.
go back to reference Ray NF, Chan JK, Thamer M, Melton LJ 3rd (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24–35PubMedCrossRef Ray NF, Chan JK, Thamer M, Melton LJ 3rd (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24–35PubMedCrossRef
7.
go back to reference Reginster JY, Gillet P, Ben Sedrine W, Brands G, Ethgen O, de Froidmont C, Gosset C (1999) Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 15:507–514PubMedCrossRef Reginster JY, Gillet P, Ben Sedrine W, Brands G, Ethgen O, de Froidmont C, Gosset C (1999) Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 15:507–514PubMedCrossRef
8.
go back to reference Lippuner K, von Overbeck J, Perrelet R, Bosshard H, Jaeger P (1997) Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporos Int 7:414–425PubMedCrossRef Lippuner K, von Overbeck J, Perrelet R, Bosshard H, Jaeger P (1997) Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporos Int 7:414–425PubMedCrossRef
9.
go back to reference Murray CJL, Lopez AD (eds) (1996) The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Global Burden of Disease and Injury Series, vol 1. Harvard University Press, Cambridge, MA Murray CJL, Lopez AD (eds) (1996) The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Global Burden of Disease and Injury Series, vol 1. Harvard University Press, Cambridge, MA
10.
go back to reference Murray CJ (1994) Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ 72:429–445PubMed Murray CJ (1994) Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ 72:429–445PubMed
11.
go back to reference Murray CJ, Acharya AK (1997) Understanding DALYs disability-adjusted life years. J Health Econ 16:703–730PubMedCrossRef Murray CJ, Acharya AK (1997) Understanding DALYs disability-adjusted life years. J Health Econ 16:703–730PubMedCrossRef
12.
go back to reference Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15:897–902PubMedCrossRef Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15:897–902PubMedCrossRef
13.
go back to reference Coale A, Guo G (1989) Revised regional model life tables at very low levels of mortality. Popul Index 55:613–643PubMedCrossRef Coale A, Guo G (1989) Revised regional model life tables at very low levels of mortality. Popul Index 55:613–643PubMedCrossRef
14.
go back to reference Malek Afzali H (1998) The life expectancy of Iranian men and women in 1996. Hakim Res J 2:107–110 Malek Afzali H (1998) The life expectancy of Iranian men and women in 1996. Hakim Res J 2:107–110
15.
go back to reference Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473PubMedCrossRef Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473PubMedCrossRef
16.
go back to reference Moayyeri A, Soltani A, Larijani B, Naghavi M, Alaeddini F, Abolhassani F (2006) Epidemiology of hip fracture in Iran: Results from the Iranian Multicenter Study on Accidental Injuries (IMSAI). Osteoporos Int 17:1252–1257PubMedCrossRef Moayyeri A, Soltani A, Larijani B, Naghavi M, Alaeddini F, Abolhassani F (2006) Epidemiology of hip fracture in Iran: Results from the Iranian Multicenter Study on Accidental Injuries (IMSAI). Osteoporos Int 17:1252–1257PubMedCrossRef
17.
go back to reference Mathers CD, Vos T, Lopez AD, Salomon J, Ezzati M (2001) Disease modeling using DISMOD. In: National Burden of Disease Studies: A Practical Guide, ed 2.0, Global Program on Evidence for Health Policy. World Health Organization, Geneva, chap 64 Mathers CD, Vos T, Lopez AD, Salomon J, Ezzati M (2001) Disease modeling using DISMOD. In: National Burden of Disease Studies: A Practical Guide, ed 2.0, Global Program on Evidence for Health Policy. World Health Organization, Geneva, chap 64
18.
go back to reference Nord E (1995) The person-trade-off approach to valuing health care programs. Med Decis Making 15:201–208PubMedCrossRef Nord E (1995) The person-trade-off approach to valuing health care programs. Med Decis Making 15:201–208PubMedCrossRef
19.
go back to reference National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int 8:S1–S88CrossRef National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int 8:S1–S88CrossRef
20.
go back to reference Williams A (1999) Calculating the global burden of disease: time for a strategic reappraisal? Health Econ 8:1–8PubMedCrossRef Williams A (1999) Calculating the global burden of disease: time for a strategic reappraisal? Health Econ 8:1–8PubMedCrossRef
21.
go back to reference Johnell O, Borgstrom F, Jonsson B, Kanis J (2006) Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos Int 18:333–337PubMedCrossRef Johnell O, Borgstrom F, Jonsson B, Kanis J (2006) Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos Int 18:333–337PubMedCrossRef
22.
go back to reference Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 17:1436–1442CrossRef Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 17:1436–1442CrossRef
Metadata
Title
Burden of Hip Fracture in Iran
Authors
S. Ahmadi-Abhari
A. Moayyeri
F. Abolhassani
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 3/2007
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-006-0242-9

Other articles of this Issue 3/2007

Calcified Tissue International 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine